Semaglutide is helping patients achieve weight loss previously achievable only with bariatric surgery. But at what cost?

Psoriasis and psoriatic arthritis (PsA) are chronic, immune-mediated inflammatory diseases associated with several shared common comorbidities, of which obesity is one of the most prevalent. A complex ...

Lexaria Bioscience Corporation (NASDAQ:LEXX) announced results from its Phase Ib study evaluating multiple GLP-1 agonists in combination with DehydraTECH (DHT). The study met its primary endpoint with ...

If you’re looking for ways to mitigate your risk of developing cardiovascular disease or experiencing a cardiac event, such as a heart attack or stroke, glucagon-like peptide-1 (GLP-1) receptor ...

A biased GLP-1 receptor agonist maintained glycemic control while reducing side effects in preclinical models. By selectively activating cAMP, this biased agonist approach may support safer diabetes ...

(HealthDay News) — Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight loss appear to be similarly effective among adults across ages, races, and starting weights, according to a review ...

Treatment with GLP-1 RAs for T2D and obesity is associated with increased risk for osteoporosis, gout, and osteomalacia compared with nonuse.

Research has suggested that GLP-1 receptor agonists may have protective effects against certain eye conditions, but they have also been linked to rare ophthalmic complications. In this retrospective ...